SPDR S&P Pharmaceuticals ETF (XPH)
| Assets | $195.41M |
| Expense Ratio | 0.35% |
| PE Ratio | 14.07 |
| Shares Out | 4.90M |
| Dividend (ttm) | $0.59 |
| Dividend Yield | 1.51% |
| Ex-Dividend Date | Mar 18, 2024 |
| Payout Ratio | 21.46% |
| 1-Year Return | -6.41% |
| Volume | 11,682 |
| Open | 39.51 |
| Previous Close | 39.58 |
| Day's Range | 39.10 - 39.53 |
| 52-Week Low | 34.67 |
| 52-Week High | 45.62 |
| Beta | n/a |
| Holdings | 42 |
| Inception Date | Jun 19, 2006 |
About XPH
Fund Home PageThe SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.
Top 10 Holdings
48.09% of assets| Name | Symbol | Weight |
|---|---|---|
| Intra-Cellular Therapies, Inc. | ITCI | 5.59% |
| Merck & Co., Inc. | MRK | 5.00% |
| Catalent, Inc. | CTLT | 4.87% |
| Eli Lilly and Company | LLY | 4.85% |
| Perrigo Company plc | PRGO | 4.81% |
| Organon & Co. | OGN | 4.77% |
| Axsome Therapeutics, Inc. | AXSM | 4.64% |
| Pfizer Inc. | PFE | 4.60% |
| Jazz Pharmaceuticals plc | JAZZ | 4.49% |
| Royalty Pharma plc | RPRX | 4.47% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 18, 2024 | $0.17298 | Mar 21, 2024 |
| Dec 18, 2023 | $0.17437 | Dec 21, 2023 |
| Sep 18, 2023 | $0.1201 | Sep 21, 2023 |
| Jun 20, 2023 | $0.12354 | Jun 23, 2023 |
| Mar 20, 2023 | $0.11537 | Mar 23, 2023 |
| Dec 19, 2022 | $0.19401 | Dec 22, 2022 |
News
Will 2023 be the year that pharma M&A makes a comeback?
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.
Final Trades: Pharma, Chevron, Uber & more
The "Halftime Report" traders give their top picks to watch for the second half.
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Pharma market investments: How ETFs help you dabble in the sector at a modest price
Some health care sector ETFs have exposure to companies like Johnson & Johnson, Pfizer, UnitedHealth
3 Pharmaceutical ETFs That Could Be Due For A Rebound
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level.
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Pharma Stocks Poised to Move Higher
Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.
President Trump signs executive orders aimed at lowering drug prices
CNBC's Meg Tirrell reports President Trump has signed four executive orders aimed at lowering drug prices. They include the U.S. allowing importation of prescription drugs from Canada and other countr...
Trump announces series of executive orders aimed at lowering drug costs
President Donald Trump on Friday signed four executive orders aimed at lowering the high cost of prescription drugs in the United States in what would make sweeping changes to the prescription drug ma...
Where this top-rated financial advisor is finding opportunities in the market now
Hightower Treasury Partners CIO Richard Saperstein outlines the areas of the market where he currently sees opportunity.
What does the investment committee recommend in health care? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Mizuho: Smaller companies are leading the way in developing vaccines for infectious diseases
Mara Goldstein of Mizuho discusses the difficulty of developing a vaccine quickly during a virus outbreak, and which large and smaller biotech and drug companies investors should be focused on.
What to Expect From Big Pharma's Earnings
We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.
Consumer strong despite recession fears, says Nuveen's Stephanie Link
Stephanie Link of Nuveen and CNBC's Mike Santoli discuss the markets after the close on "Closing Bell."
Tech stocks facing regulations no matter the midterm outcome?
Hedge fund manager Jonathan Hoenig on the impact of the midterm elections on the markets.